◈ Nootpedia
Compact view
Research pass: medium Supplement · Capsule SKIP-FOR-NOW HIGH

Muscimol

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW HIGH

Recreational dissociative profile with no cognitive use case; theanine + magnesium + tryptophan/glycine cleaner for sleep/anxiety; gummy market is a vendor lottery with documented adulteration, hospitalizations, and deaths (Diamond Shruumz 2024).

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan)
    SKIP-FOR-NOW

    Recreational dissociative with hours of impairment, no cognitive upside. Already has theanine 200mg, magnesium glycinate + threonate, and L-tryptophan (post-V5) covering anxiolysis and sleep with vastly cleaner profiles. Adding GABA-A direct agonism at age 20 with developing neural plasticity is downside-only.

  • 30-50, executive maintenance
    SKIP

    No cognitive case; same cleaner alternatives apply.

  • 50+, mild cognitive decline
    SKIP

    GABA-A agonism in older adults raises fall risk and worsens cognition acutely; especially poor fit.

  • Anxiety-prone
    SKIP

    Ashwagandha, theanine, magnesium, propranolol PRN, low-dose buspirone, or properly prescribed benzo PRN all dominate. Muscimol's dissociation profile is wrong for daily anxiolysis.

  • High athletic load, tested status
    SKIP

    Not WADA-banned but the next-day residual sedation kills training quality. Vomiting risk during/after training is real.

  • Sleep-disordered
    SKIP

    Trazodone, magnesium glycinate, glycine, tryptophan, apigenin, even doxepin 3-6mg all clean alternatives. Muscimol-induced sleep is dissociative and grogginess-prone, not restorative.

  • Recovery-focused (post-injury, post-illness)
    SKIP

    No anabolic or anti-inflammatory case; ataxia + nausea + impairment counterproductive to rehab.

  • Strength/anabolic-focused
    SKIP

    No anabolic action; sedation + appetite disruption work against goals.

▸ Subjective experience (deep)

Onset: 30 min - 2 hr (highly variable with food, body weight, prep method). Peak: 1-3 hr. Duration: 4-8 hr active; some effects persist up to 24 hr (residual sedation, dream-like states).

Low dose (5-7 mg muscimol): Mild relaxation, body warmth, slight dissociation, mild anxiolysis. Often described as "GABAergic" but qualitatively heavier and weirder than alcohol or benzos.

Standard psychoactive (8-15 mg): Sedation, ataxia, slurred speech, vivid dream-like states with eyes closed, dissociation from body and time, nausea, perceptual distortion. Not classically psychedelic — no visuals like psilocybin/LSD. Often profound sleep with intense dreams.

Higher (>15 mg or unpredictable gummy doses): Delirium, confusion, severe ataxia, vomiting, autonomic dysregulation (sweating, salivation from accompanying muscarine in raw mushroom), occasional seizures. Hours of being non-functional.

Common across all doses:

  • Nausea / vomiting (very common, especially with raw or under-decarboxylated material)
  • Loss of motor coordination
  • Time distortion
  • Drowsiness lasting into next day
  • Memory gaps at higher doses

Variability is enormous because (a) ibotenic-to-muscimol ratio depends on preparation, (b) individual mushrooms vary 10-fold in alkaloid content, (c) commercial gummies have shown wildly inconsistent dosing and frequent adulteration with non-listed substances (synthetic cannabinoids, kratom alkaloids, NBOMe analogs in some Diamond Shruumz tests).

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Moderate cross-tolerance with other GABA-A ligands; rapid tolerance to subjective effects with daily use anecdotally
  • Recommended cycle: N/A — not recommended at all
  • Reset protocol: N/A
▸ Stacking deep dive

Synergistic with

None recommended. Theoretically additive with anything GABAergic or sedating, which is the problem, not the feature.

Avoid stacking with

  • Alcohol: Additive CNS depression; multiple deaths in case reports involve co-use
  • Benzodiazepines, Z-drugs: Synergistic respiratory depression
  • phenibut: GABA-A direct agonism + GABA-B agonism = compounded sedation, dependence on phenibut side worsens
  • baclofen: Same — GABA-A + GABA-B layered depression
  • gaba-supplement: No real interaction (oral GABA barely crosses BBB) but redundant intent
  • Opioids, barbiturates, ketamine: Compounded CNS depression, respiratory depression

Neutral / safe co-administration

N/A — not using.

▸ Drug interactions deep dive

Unstudied formally. Theoretical CYP interactions minimal — muscimol is mostly excreted unchanged or via simple conjugation. Real interaction risk is pharmacodynamic: anything CNS-depressant compounds the sedation/respiratory depression risk.

No specific contraceptive interactions documented.

▸ Pharmacogenomics

No characterized polymorphisms drive muscimol response in published literature. δ-GABA-A subunit variants (GABRD) plausibly modulate sensitivity but no actionable data.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Gas station / smoke shop gummies Various (MoonWlkr, Wunder, Hamilton's, Psyched Wellness, etc.) $20-50/pack LOW FDA warning letters issued 2024-2025; CDC found Schedule I adulterants in some "nootropic" Amanita gummies (Charlottesville 2023-24 cluster)
Whole dried mushroom (online ethnobotanical) iAmShaman, others $20-60/oz MEDIUM Alkaloid content varies 10-fold between mushrooms; user-driven decarboxylation required
Pure muscimol (research chemical) Sigma-Aldrich, Cayman Chemical ~$200-400/100mg HIGH (purity) Research-use-only labeling; not for human consumption
Tinctures / extracts Psyched Wellness "Calm" etc. $40-80/bottle MEDIUM-LOW Better dosing consistency than gummies but still in FDA crosshairs

FDA position (Dec 2024 letter to industry): Amanita muscaria, its extracts, muscimol, ibotenic acid, and muscarine are unapproved food additives. Food containing them is adulterated under the FFDCA. Enforcement actions continue 2025+.

No legitimate medical sourcing path in US.

▸ Biomarkers to track (deep)

N/A — not using.

▸ Controversies / open debates Live debate
  • "It's natural" framing. Used heavily by gummy vendors. Irrelevant — death cap (Amanita phalloides) is also natural. Mechanism, dose, and quality matter; phylogeny doesn't.
  • Mechanism vs. clinical reality. Muscimol's direct GABA-A orthosteric agonism is a genuinely interesting and rare profile in available compounds — most "GABAergic" options are PAMs (benzos, Z-drugs) or indirect. The mechanism alone has theoretical appeal (different from benzo tolerance/dependence pattern). But the actual subjective profile is worse, not better, than benzos for daily use — more dissociation, more delirium, less clean anxiolysis. Mechanism-novelty doesn't redeem profile.
  • Microdosing claims vs. zero clinical evidence. Vendors and a handful of retrospective case reports promote sub-threshold Amanita microdosing for anxiety/sleep. No RCTs. The plural of anecdote isn't data, and the vendor incentive structure is obvious.
  • Russian/Siberian traditional use vs. modern context. Real ethnobotanical history (Sámi, Koryak, Itelmen). But traditional use was ceremonial/shamanic with cultural infrastructure for managing the experience, not daily wellness supplementation. Importing the substance without the context misuses both.
  • Western vs. Eastern European pharmacology research. Eastern European literature (Polish, Russian) has more case-report and traditional-use depth on Amanita; Western literature focuses on toxicology and receptor pharmacology. Neither side has produced clinical efficacy evidence for any therapeutic claim.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-FOR-NOW (HIGH confidence). Recreational dissociative profile, no cognitive use case, FDA enforcement environment hot, gummy market is adulteration-risk lottery, Dylan's existing GABAergic stack (theanine + magnesium + tryptophan) covers the legitimate sleep/anxiety territory more cleanly. Not worth depth-researching further.
▸ Open questions / gaps Open
  • What would change verdict? Honestly, nothing realistic in the next 5 years. Would require: (1) FDA-approved pure muscimol product with dose accuracy, (2) RCT data showing meaningful efficacy on a specific indication, (3) safety data showing it cleanly outperforms theanine/magnesium/tryptophan/PRN benzo for that indication. None of those are likely. Even Psyched Wellness's clinical work (early-stage) targets sleep — a domain Dylan already has covered.
  • Microdose research: A real RCT (n>100, controlled, validated outcomes) on sub-threshold Amanita extract for anxiety or sleep would be informative. Not aware of any in flight that would publish before 2028+.
  • Standalone pure-muscimol pharma. If a pharma company developed a controlled-dose muscimol product (low-dose, possibly transdermal or sublingual) with reliable PK, that would be a different evaluation. Not currently in the pipeline.
▸ Sources (full, with our context)
Back to compact view